Incidence of Bacille Calmette-Guérin associated lymphadenitis in healthy children: A systematic review and meta-analysis.

Hum Vaccin ImmunotherMay 4, 2026 (epub)
Clinical ResearchPediatricsOpen access

BongKyoo Choi, Hyunjeong Cho, Ju-Yeun Lee et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the incidence of Bacille Calmette-Guérin (BCG) lymphadenitis in healthy children, analyzing data from 52 studies involving approximately 1.8 million children. The pooled incidence proportion was found to be 2.5% (95% CI, 1.6-3.6). The study revealed significant variability in incidence based on surveillance methods and study design.

Key findings

  • The pooled incidence proportion of BCG lymphadenitis was 2.5% (95% CI, 1.6-3.6).
  • Active surveillance reported a significantly higher incidence proportion compared to passive surveillance.
  • Randomized controlled trials showed a higher incidence than prospective and retrospective cohort studies.
  • Incidence varied significantly based on study quality, publication period, and BCG strain.

Why it matters

Understanding the incidence of BCG lymphadenitis is crucial for clinicians to assess the risk associated with BCG vaccination in children. Variability in reported outcomes can inform vaccination strategies and patient counseling.

Source

PubMed · PMID 42081288Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.